Chol-CTPP

CAT: 804-HY-144825Size: 1 EachDry Ice: NoHazardous: No
1 EachSelected
AVAILABILITY
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Chol-CTPP is a ligand with dual targeting effect on blood-brain barrier (BBB) and glioma cells. Lip-CTPP can be gained by Chol-CTPP and another mitochondria targeting ligand (Chol-TPP) . Lip-CTPP is a promising potential carrier to exert the anti-glioma effect of doxorubicin (DOX) and lonidamine (LND) collaboratively. Lip-CTPP elevates the inhibition rate of tumor cell proliferation, migration and invasion, promote apoptosis and necrosis, and interfere with mitochondrial function[1].
UNSPSC
12352005
Target
Apoptosis; Reactive Oxygen Species (ROS)
Type
Reference compound
Related Pathways
Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/chol-ctpp.html
Solubility
10 mM in DMSO
Smiles
O=C(C1=CC=C(C=C1)O)NCCOCCNC(C(CCCC2)=C2C(NCCCCCC(OCCO[C@@H](CC3)CC4=CC[C@]([C@@]5([H])[C@](CC6)([C@@](CC5)([H])[C@H](C)CCCC(C)C)C)([H])[C@@]6([H])[C@]43C)=O)=O)=O.[3].[44]
Molecular Formula
C144H263N3O53
Molecular Weight
2884.62
References & Citations
[1]Jiaqi Lu, et al. Multiple targeted doxorubicin-lonidamine liposomes modified with p-hydroxybenzoic acid and triphenylphosphonium to synergistically treat glioma. Eur J Med Chem. 2022 Feb 15;230:114093.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported